Form 4: ARS Pharmaceuticals Director Acquires Stock Options
SEC Form 4 Filing
Director Pratik Shah acquired 40,000 stock options in ARS Pharmaceuticals, Inc. on June 20, 2024.
Summary
- Pratik Shah, a director of ARS Pharmaceuticals, Inc. (SPRY), acquired 40,000 stock options on June 20, 2024.
- The options have an exercise price of $7.73.
- The options vest fully on the earlier of June 20, 2025, or the date of the Issuer's 2025 annual meeting of stockholders.
- The options expire on June 19, 2034.
- Following the transaction, Mr. Shah directly owns 40,000 derivative securities.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine filing related to stock option grants. The acquisition of options by a director is generally viewed as a positive, but it's not a major event.
Positives
- The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders. This filing indicates a director's acquisition of stock options, which is a common form of executive compensation.
Stakeholder Impact
- The acquisition of stock options by a director could have a slightly positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 06/20/2024 | Date of the transaction: acquisition of stock options. |
| 06/20/2025 | Earliest vesting date for the stock options. |
| 06/19/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.